PROSPER CRPC Data to Be Released 2 Years Earlier Than Expected
Published: Monday, Jun 12, 2017
Astellas Pharma and Pfizer have announced that phase III results from the PROSPER trial of enzalutamide (Xtandi) in men with nonmetastatic castration-resistant prostate cancer (CRPC) will be ready later this year. Previously, those data weren’t scheduled for release until June 2019.
... to read the full story